SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR 1 ...

Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...

Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision ...

Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework Observational studies or ...

Over 80% of patients with lung cancer receive community care, risking gaps in care quality and delivery. ACCC's initiative identified barriers to biomarker testing and care delivery for early-stage ...

Leronlimab increases PD-L1 expression on circulating tumor cells, potentially converting "cold" tumors to "hot" ones, enhancing immune response in metastatic triple-negative breast cancer. In a study, ...

Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...

The FDA is reassessing the approval of immune checkpoint inhibitors for treating advanced HER2-negative gastric adenocarcinoma, questioning their broad application regardless of patients’ PD-L1 ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Diaceutics PLC, (AIM: DXRX), today announces the launch of DXRX – The Diagnostic Network® which has been designed to accelerate the end-to-end development and ...

Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., announced new findings that show MHC-II protein expression is a more reliable predictor of response to pembrolizumab (Keytruda®) than the ...